Session » Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

Date: Tuesday, November 14, 2023

Time: 2:00PM-3:30PM

Meeting: ACR Convergence 2023

Abstract Number: 2479

Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease

Abstract Number: 2480

Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI

Abstract Number: 2481

Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy

Abstract Number: 2482

Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis

Abstract Number: 2483

CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort

Abstract Number: 2484

Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.